1. Home
  2. PWM vs COEP Comparison

PWM vs COEP Comparison

Compare PWM & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PWM
  • COEP
  • Stock Information
  • Founded
  • PWM 2018
  • COEP 2017
  • Country
  • PWM Hong Kong
  • COEP United States
  • Employees
  • PWM N/A
  • COEP N/A
  • Industry
  • PWM
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PWM
  • COEP Health Care
  • Exchange
  • PWM Nasdaq
  • COEP Nasdaq
  • Market Cap
  • PWM 34.6M
  • COEP 32.4M
  • IPO Year
  • PWM 2023
  • COEP N/A
  • Fundamental
  • Price
  • PWM $0.87
  • COEP $13.17
  • Analyst Decision
  • PWM
  • COEP
  • Analyst Count
  • PWM 0
  • COEP 0
  • Target Price
  • PWM N/A
  • COEP N/A
  • AVG Volume (30 Days)
  • PWM 1.2M
  • COEP 111.7K
  • Earning Date
  • PWM 02-13-2025
  • COEP 03-25-2025
  • Dividend Yield
  • PWM N/A
  • COEP N/A
  • EPS Growth
  • PWM N/A
  • COEP N/A
  • EPS
  • PWM N/A
  • COEP N/A
  • Revenue
  • PWM $639,912.00
  • COEP N/A
  • Revenue This Year
  • PWM N/A
  • COEP N/A
  • Revenue Next Year
  • PWM N/A
  • COEP N/A
  • P/E Ratio
  • PWM N/A
  • COEP N/A
  • Revenue Growth
  • PWM N/A
  • COEP N/A
  • 52 Week Low
  • PWM $0.45
  • COEP $2.31
  • 52 Week High
  • PWM $2.70
  • COEP $13.70
  • Technical
  • Relative Strength Index (RSI)
  • PWM 38.31
  • COEP 66.28
  • Support Level
  • PWM $0.45
  • COEP $8.65
  • Resistance Level
  • PWM $1.27
  • COEP $12.95
  • Average True Range (ATR)
  • PWM 0.35
  • COEP 1.60
  • MACD
  • PWM -0.06
  • COEP -0.11
  • Stochastic Oscillator
  • PWM 18.67
  • COEP 89.50

About PWM Prestige Wealth Inc.

Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Share on Social Networks: